Imperial College London Limited

Address: Paddington, Norfolk Place

Sponsor Overview

assignment

Specializations

Neurocognitive Health and Dementia Prevention

Clinical research activity includes older adults at elevated dementia risk who remain free of overt cognitive impairment, with a focus on preserving cognitive function and slowing decline. The work centres on multimodal prevention strategies in people enriched for APOE ε4 risk.

cognitive decline
dementia prevention
multimodal lifestyle intervention
metabolic support

Interest in this area reflects a therapeutic emphasis on maintaining brain health in ageing populations with identifiable risk factors for neurodegenerative disease.

HIV and Viral Remission Maintenance

Research activity in HIV focuses on sustaining virological control after interruption of standard treatment, with attention to immune-based approaches that support longer periods of remission. The sponsor’s portfolio includes studies of broadly neutralising antibody strategies aimed at controlling viral rebound.

HIV remission
broadly neutralising antibodies
viral suppression
antiretroviral-free control

This area highlights a therapeutic interest in advanced immunotherapy for chronic viral disease.

Eosinophilic Granulomatosis with Polyangiitis

Clinical studies also address eosinophilic granulomatosis with polyangiitis (EGPA), a complex vasculitic and eosinophilic inflammatory disorder. The research examines treatment options intended to maintain remission and improve disease control in adults with this rare immune-mediated condition.

EGPA
vasculitis
eosinophilic inflammation
remission maintenance

The therapeutic focus lies in targeted management of severe inflammatory disease with potential relevance to specialised respiratory and immunology care.

Immune and Inflammatory Therapeutics

Across its funded trials, the sponsor shows a strong interest in immune modulation and interventions that act on inflammatory or antiviral pathways. This includes work spanning chronic infection, systemic inflammation, and conditions where targeted biologic approaches may alter disease course.

biologic therapy
immune-mediated disease
inflammatory pathway targeting
chronic disease control

The portfolio reflects engagement with therapies relevant to specialist medicine, including neurology, infectious disease, and rheumatology.

Trial Name	Country	Status
Evaluation of Antiretroviral Therapy Combined with 10-1074-LS and Teropavimab in Primary or Early HIV Infection: A Randomized, Placebo-Controlled Trial	Belgium Denmark Germany Spain Sweden The Netherlands	Recruiting
Multimodal METformin and FINGER lifestyle intervention to prevent cognitive impairment and disability in older adults at risk for dementia: a phase IIb multi-national randomised, controlled trial.	Finland Sweden	Not Recruiting
Randomized, Double-Blind, Placebo-Controlled Study of Tezepelumab in Adults with Eosinophilic Granulomatosis with Polyangiitis (EGPA)	Italy	Not Yet Recruiting